-
摘要:
骨髓增生异常综合征（MDS）是一类造血干细胞恶性克隆性疾病，其治疗主要集中在表观遗传学治疗、化疗、干细胞移植以及新药方面，现将各种治疗方法进行综述。
Abstract:Myelodysplastic syndrome (MDS) is a kind of hematological malignancies, characterized by malignant clones in hematopoietic stem cells. The treatment mainly focused on epigenetic treatment, chemotherapy, stem cell transplantation and new drugs. This article summarized all these kinds of treatments.
-
Key words:
- Myelodysplastic syndrome /
- High-risk /
- Treatment
-
Competing interests: The authors declare that they have no competing interests.作者贡献李世俊：文献检索及文章撰写齐军元：文章审校
-
[1] Dı´ez-Campelo M, Lorenzo JI, Itzykson R, et al. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries[J]. Br J Haematol, 2018, 181(3): 350-359. doi: 10.1111/bjh.15190
[2] Pappa V, Anagnostopoulos A, Eleni Bouronikou E, et al. A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real world clinical setting in Greece[J]. Int J Hematol, 2017, 105(2): 184-195.
[3] 张前鹏, 韩永胜, 皖湘, 等.地西他滨与传统化疗治疗中、高危骨髓增生异常综合征的临床比较[J].中国实验血液学杂志, 2018, 26(1): 197-201. Zhang QP, Han YS, Wan X, et al. Comparison of decitabine rigimen and traditional chemotherapy regimen in treatment of patients with intermediate or high-risk myelodysplastic syndrome[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2018, 26(1): 197-201.
[4] Li H, Wang L, Wu Y, et al. Very-Low-Dose decitabine is effective in treating intermediate- or high-risk myelodysplastic syndrome[J]. Acta Haematol, 2017, 138(3): 168-174. http://www.ncbi.nlm.nih.gov/pubmed/29045939
[5] Chang CK, Zhao YS, Xu F, et al. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes[J]. Br J Haematol, 2017, 176(4): 600-608. http://www.ncbi.nlm.nih.gov/pubmed/27984642
[6] Schuler E, Zadrozny N, Blum S, et al. Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive Chemotherapy[J]. Ann Hematol, 2018, 97(12): 2325-2332. doi: 10.1007/s00277-018-3466-7
[7] de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel[J]. Blood, 2017, 129(13): 1753-1762. http://www.sciencedirect.com/science/article/pii/S0006497120335345
[8] Sengsayadeth S, Labopin M, Boumendil A, et al. Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the European society for blood and bone marrow transplantation study[J]. Biol Blood Marrow Transplant, 2018, 24(7): 1406-1414. http://europepmc.org/abstract/MED/29536560
[9] Nishihori T, Perkins J, Mishra A, et al. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome[J]. Biol Blood Marrow Transplant, 2014, 20(6): 776-780. http://www.sciencedirect.com/science/article/pii/S1083879114000950
[10] Sohn SK, Moon JH. Survey of expert opinions and related recommendations regarding bridging therapy using hypomethylating agents followed by allogeneic transplantation for high-risk MDS[J]. Crit Rev Oncol Hematol, 2015, 95(2): 243-250. http://europepmc.org/abstract/MED/25840907
[11] Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneie stem cell transplantation[J].Leukemia, 2013, 27(6): 1229-1235. http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=89447404&site=ehost-live
[12] Mo X, Zhang X, Xu L, et al. Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation[J]. Front Med, 2019(13): 354-364. http://www.cqvip.com/QK/71235X/201903/7002257796.html
[13] Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial[J]. Lancet Haematol, 2020, 7(4): e309-e319. http://www.sciencedirect.com/science/article/pii/S2352302619302844
[14] Savona MR, Pollyea DA, Stock W, et al. PhaseⅠB study of glasdegib, a Hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS[J]. Clin Cancer Res, 2018, 24(10): 2294-2303.
[15] Reidel V, Kauschinger J, Hauch RT, et al. Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile[J]. Oncotarget, 2018, 9(25): 17270-17281. http://europepmc.org/abstract/MED/29707107
[16] Zeidan AM, Knaus HA, Robinson TM, et al. A Multi-center Phase Ⅰ Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure[J]. Clin Cancer Res, 2018, 24(15): 3519-3527.
[17] Montoro J, Gallur L, Merchan B, et al. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes[J]. Ann Hematol, 2018, 97(8): 1349-1356.
[18] Chen Y, Kantarjian H, Estrov Z, et al. A Phase Ⅱ Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities[J]. Clin Lymphoma Myeloma Leuk, 2012, 12(5): 341-344.
[19] Zeidan AM, Smith BD, Carraway HE, et al. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia[J]. Br J Haematol, 2017, 176(2): 241-247. http://www.ncbi.nlm.nih.gov/pubmed/27790720
[20] Jain P, Klotz J, Dunavin N, et al. Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia[J]. Leuk Res Rep, 2017, 7: 40-44. http://www.sciencedirect.com/science/article/pii/S2213048917300110
[21] Chokr N, Farooq H, Guadalupe E. Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab[J]. Case Rep Oncol Med, 2018, 2018: 8981375. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830024/
[22] Sallman DA, Davila ML. Is Disease-Specific Immunotherapy a Potential Reality for MDS?[J]. Clin Lymphoma Myeloma Leuk, 2017, 17S: S26-S30. http://www.sciencedirect.com/science/article/pii/S2152265017300265
[23] Zeidan A, Zeidner J, Duffield A, et al. Stabilization of myelodysplastic syndromes (MDS) following hypomethylating agent (HMAs) failure using the immune checkpoint inhibitor ipilimumab: a phase Ⅰ trial[J]. Blood, 2015, 126(23): 1666.
[24] Sanford D, Garcia-Manero G, Jorgensen J, et al. CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count[J]. Leuk Lymphoma, 2016, 57(8): 1965-1968. http://www.ncbi.nlm.nih.gov/pubmed/26726757
[25] Jabbour E, Garcia-Manero G, Cortes J, et al. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast-Phase Chronic Myeloid Leukemia[J]. Clin Lymphoma Myeloma Leuk, 2012, 12(4): 244-251. http://www.sciencedirect.com/science/article/pii/S2152265012000511
[26] Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside[J]. Blood, 2002, 99(12): 4343-4349. http://www.ncbi.nlm.nih.gov/pubmed/12036860?dopt=Abstract
[27] Sekeres MA, Maciejewski JP, Erba HP, et al. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia[J]. Cancer, 2011, 117(6): 1253-1261. http://www.ncbi.nlm.nih.gov/pubmed/20960521
[28] Daver N, Kantarjian H, Ravandi F, et al. A phase Ⅱ study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome[J]. Leukemia, 2016, 30(2): 268-273
[29] Natarajan-Amé S, Park S, Ades L, et al. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase Ⅰ/Ⅱ Study by the GFM[J]. Br J Haematol, 2012, 158(2): 232-237. http://www.ncbi.nlm.nih.gov/pubmed/22571447
[30] Rettig MP, Godwin J, Vey N, et al. Preliminary translational results from an ongoing phase 1 study of flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: rationale for combining flotetuzumab and anti-PD-1/PD-L1 immunotherapies[J]. Blood, 2017, 130(Suppl 1): 1365.
[31] 张婧玲, 曹颖平, 李景岗.地西他滨联合CAG治疗中、高危骨髓增生异常综合征及急性髓系白血病的疗效与安全性的Meta分析[J].中国实验血液学杂志, 2019, 27(2): 494-503. Zhang JL, Cao YP, Li JG. Efficacy and safety of decitabine combined with CAG (Cytarabine, Aclarubicin, G-CSF) for patients with intermediate or high risk myelodysplastic syndrome and acute myeloid leukemia: a meta-analysis[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2019, 27(2): 494-503.
[32] Mittelman M, Filanovsky K, Ofran Y, et al. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol[J]. Ann Hematol, 2016, 95(11): 1811-1818. doi: 10.1007/s00277-016-2776-x?view=classic
[33] Boddu P, Kantarjian H, Garcia-Manero G, et al. The emerging role of immune check point based approaches in AML and MDS[J]. Leuk Lymphoma, 2018, 59(4): 790-802. http://www.ncbi.nlm.nih.gov/pubmed/28679300
[34] Pericole FV, Lazarini M, Paiva LBd, et al. BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes[J]. Front Oncol, 2019, 9: 16. http://www.researchgate.net/publication/330711346_BRD4_Inhibition_Enhances_Azacitidine_Efficacy_in_Acute_Myeloid_Leukemia_and_Myelodysplastic_Syndromes
[35] Björklund AT, Carlsten M, Sohlberg E, et al. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML[J]. Clin Cancer Res, 2018, 24(8): 1834-1844. http://www.researchgate.net/publication/323192153_Complete_Remission_with_Reduction_of_High-risk_Clones_following_Haploidentical_NK_Cell_Therapy_against_MDS_and_AML
[36] Ma Y, Shen J, Wang LX. Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion[J]. Medicine (Baltimore), 2018, 97(16): e0434. https://www.zhangqiaokeyan.com/academic-journal-foreign-pmc_detail_thesis/040005261861.html
[37] Stevens BM, Zhang W, Pollyea DA, et al. CD123 CAR T cells for the treatment of myelodysplastic syndrome[J]. Exp Hematol, 2019, 74: 52-63. http://www.researchgate.net/publication/325544101_Anti-CD123_CAR_T-Cell_Therapy_for_the_Treatment_of_Myelodysplastic_Syndrome
[38] Stevens BM, Khan N, D'Alessandro A, et al. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes[J]. Nat Commun, 2018, 9(1): 3694. http://www.onacademic.com/detail/journal_1000040441866110_8008.html
[39] Zhang W, Stevens BM, Budde EE, et al. Anti-CD123 CAR T-cell therapy for the treatment of myelodysplastic syndrome[J]. Blood, 2017, 130(Suppl 1): 1917. http://www.researchgate.net/publication/325544101_Anti-CD123_CAR_T-Cell_Therapy_for_the_Treatment_of_Myelodysplastic_Syndrome
[40] Qazilbash MH, Wieder E, Thall PF, et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies[J]. Leukemia, 2017, 31(3): 697-704.
[41] 徐孟, 陈斌.陈斌教授治疗骨髓增生异常综合征经验[J].中西医结合研究, 2017, 9(5): 275-276, 278. doi: 10.3969/j.issn.1674-4616.2017.05.021 Xu M, Chen B. Professor Chen Bin's experience in treatment of myelodysplastic syndrome[J]. Zhong Xi Yi Jie He Yan Jiu, 2017, 9(5): 275-276, 278. doi: 10.3969/j.issn.1674-4616.2017.05.021
[42] 周振环, 杨淑莲, 王茂生, 等.中西医结合治疗高危骨髓增生异常综合征33例[J].浙江中医杂志, 2018, 53(12): 864. doi: 10.3969/j.issn.0411-8421.2018.12.004 Zhou ZH, Yang SL, Wang MS, et al. The combined treatment of traditional chinese medicine and western medicine in 33 patients with high-risk myelodysplastic syndrome[J]. Zhejiang Zhong Yi Za Zhi, 2018, 53(12): 864. doi: 10.3969/j.issn.0411-8421.2018.12.004
计量
- 文章访问数: 2844
- HTML全文浏览量: 571
- PDF下载量: 1536
下载:
